Discovery & Development Europe 2025 (Light Version)

23 - 24 June 2025 | Basel, Switzerland

Pushing traditional boundaries in pharmaceutical science by
accelerating the discovery & development of novel therapeutics

Discovery & Development US 2025

Unlocking Future Insights in Biomedicine Research & Development

NextGen Biomed connects thought leaders, researchers and experts with pharmaceutical & biotech representatives to discuss the latest innovations in biomedicine discovery & development.

There will be six dedicated programmes running across three full days, which together will explore the entire value chain involved in bringing next-generation biomedicines to market, making this a must-attend event for anyone working in biotherapeutics discovery, development & manufacturing.

Hear from past attendees of last year's Biologics 2024 conference

Overview Discovery & Development Formulation & Delivery

Explore Discovery & Development Europe 2025: Guiding Biopharma From Target Identification To Clinical Candidate

Connect & collaborate with 1000+ leaders in biology and chemistry at the renowned Discovery & Development Summit in Basel, where we provide a platform to help you make informed pipeline decisions in early R&D & accelerate the route from target identification to novel clinical candidate, ultimately increasing the number of life-saving treatments for those with critical illnesses.

Together with Formulation & Delivery, benefit from an event supporting you to identify potential formulation & delivery bottlenecks and issues before they arise and promoting collaboration to ensure the development of optimised drug products.

Discovery Europe 2025

Across 12 specialized topic tracks and 100+ presentations, our congress touches on all aspects of the drug development journey, regardless of disease area or modality. Hear how experts are utilizing the latest technologies for target identification & validation and exactly how these are being translated into the preclinical phase. Gain exclusive insights into the current innovation in the space with novel biologic & small molecule targets, including ADCs, cell and gene therapies, PROTACs, molecular glues & more!

Packed with interactivity, networking and engaging talks, our Discovery Europe event will equip you with the knowledge & connections needed to keep ahead of the trends & make rapid advancements within your R&D.

 

Agenda at a Glance


Day 1

  • Track 1: Target Identification & Validation
  • Track 2: Medicinal & Computational Chemistry
  • Track 3: Translating Targets Into Therapies
  • Track 4: Novel Large Molecule Targets
  • Track 5: Targeting Neurodegeneration & Age-Related Disease
  • Track 6: Lab Digitalization & Connectivity

Day 2

  • Track 1: Functional Genomics & Cellular Technologies
  • Track 2: Hit Identification & Screening
  • Track 3: DMPK, Pharmacology & Safety
  • Track 4: Novel Small Molecule Targets
  • Track 5: Targeting Neuroimmunology & Neuroinflammation
  • Track 6: Implementing Automation & Robotics

Formulation & Drug Delivery Congress

Join over 1000 cross-industry experts at Formulation & Delivery 2025 connecting pharmaceutical & biotech representatives as well as academia for high-level discussions on the latest innovations in pharmaceutical drugs formulation, drug delivery, RNA development & Peptides and Oligonucleotide design. 

Across two days our programme will include 8 specialised topic areas diving into specific developments within the industry, from formulation strategies for cell and gene therapies, PROTACs and Nanotechnology to the latest advancements in enhancing bioavailability.

Our Formulation & Delivery event will be co-located with Discovery Europe 2025 in Basel. Enjoy the collaboration as we support your engagement with discovery and formulation colleagues to ensure a smoother development of optimised drug products. 

Leading expert scientists working across formulation, drug delivery, bioanalysis, developability, and manufacturing science & technologies, representing global pharmaceutical organisations, leading biotechnology companies and internationally renowned academic institutions. 

Over 50 technical presentations and case studies focused on the critical topics in AI for automated formulations, enhanced drug delivery through vaccines, PROTAC, and exosomes, as well as an exploration of sustainable drug development.

Agenda at a Glance


Day One

  • Track 1: Small Molecule Formulation
  • Track 2: Large Molecule Delivery
  • Track 3: Preformulation Studies

Day Two

  • Track 1: Large Molecule Formulation
  • Track 2: Small Molecule Drug Delivery
  • Track 3: Process Chemistry & Pharmaceutical Materials Analysis

What to Expect at Discovery & Development Europe 2025

Networking & knowledge-sharing is at the heart of what we do. With 240 pre-arranged 1-2-1 meetings and over 12 hours of networking, don't miss the opportunity to connect with 1,000 leaders from across the R&D ecosystem

Engaging Thought Leadership
Experience over 100 presentations and interactive discussions, with best practice from industry leaders to guide your novel programmes from target ID to clinical candidate.

Global Technology Showcase
An international exhibition showcasing cutting-edge technologies and services from premier providers in the scientific field.

Networking Emphasis
Unparalleled networking opportunities, including personalised 1-2-1 meetings, vibrant drinks reception, and informal gatherings to foster meaningful connections.

Start-up Zone & Poster Presentations
Inspiring Start-Up Pitches and Academic Posters  unveiling the latest breakthroughs from emerging biotechs and academic spin-outs.

NextGen Biomed - What to Expect Presenting 1
NextGen Biomed - What to Expect Exhibiting 1
NextGen Biomed - What to Expect Networking 2
1000

leading pharma, biotech, investor & academic delegates

240
pre-arranged 1-2-1 meetings, facilitating business growth
55
hours of presentations, discussions & interactive content
9
hours of networking breaks, including  refreshments

Discovery & Development Europe 2025 Programme Highlights

Explore dynamic panels, engaging roundtables, and hands-on workshops designed to drive innovation and foster collaboration in Drug Discovery, Formulation and Delivery including: 

Drug Discovery

Roundtable: PROTACs – Drugging The ‘Undruggable’

  • Enhancing PROTAC design, potency & safety
  • Delivery challenges

 

Roundtable: The Future Of Antibody-Drug Conjugates (ADCs)

  • Enhancing ADC design, potency & safety
  • Delivery challenges

Panel Discussion: Novel Platforms & Techniques To Improve Hit Identification

 

•    Optimising Hit discovery
•    Minimising false positives
•    Integration of techniques

Panel Discussion: Fostering Partnerships & Collaboration In 2025 – as part of our newly introduced Early-Stage R&D Innovation Programme

 

  • Emerging technologies & techniques
  • Cross-sector partnership
  • Open innovation

 

Moderated by Alexander Natz, Secretary General, EUCOPE

Panel Discussion: The Investment Landscape In 2025 – Time To Rethink?


•    Importance of aligning scientific innovation with commercial potential
•    Emerging strategies


Panellists include Christoph Rösli, Director of Research Bern, CSL Behring & Member of the Selection Board, BaseLaunch; David Jenkinson, Head of Childhood Cancer Translational Challenge, LifeArc; David Dexter, Director of Research, Parkinsons UK & more to be confirmed!

Panel Discussion: AI-Powered Technological Advancements For Novel Target Discovery


•    Novel platforms & techniques to identify new targets
•    Utilising AI/ML
•    Challenges & future opportunities


Panellists:
Giovanni Spagnolli, Chief Technology Officer, Sibylla Biotech
Ian Roberts, Director of Therapeutic Technology, Healx

Panel Discussion: Fostering Collaboration To Accelerate Neurodegenerative Disease Research


•    Pharma, biotech & academic partnerships
•    The need for innovation, data & technology in CNS research
•    Challenges to be solved through collaboration 

Moderated by Emma Mead, Chief Scientific Officer, Alzheimer’s Research UK Oxford Drug Discovery Institute, University of Oxford. Panellists include Knut Biber, Research Fellow & Head of Glial Biology Team, AbbVie; Sarah Jolly, Principal Scientist, LifeArc; Michael Johnson, Professor of Neurology & Genomic Medicine, Imperial College London


Day 2 Breakfast Workshop - LifeArc: Biomarkers In Neurodegenerative Diseases: From Detection To Progression - Are Blood -Based Biomarkers Enough?

  • Beyond blood-based biomarkers?
  • Are we any closer to a solution?
  • Application of AI/ML

Moderated by Manuela Cerina, Scientific Director – Neurodegeneration, LifeArc & Giovanna Lalli, Director of Strategy & Operations, LifeArc

Panel Discussion:
Automation & Robotics In Drug Discovery & Development – Where Are We Now? 


•    Impact of automation 
•    AI/ML  
•    Robotics in lab processes

Moderated by Rekha Lakshmanan, Global Head of Data Office, AstraZeneca

Day 2 Breakfast Workshop: SiLA & AnIML Splash


•    Splash! Is a unique event for every digital lab enthusiast. It combines an educational part with a hands-on session to try out standards in action. Pick up the details on the popular SiLA and AnIML standards, understand how they work and where you can put them to use. Our hands-on session lets you experience the standards in action firsthand. We’re bringing real and cloud-based instruments and lots of example data sets 
•    Feel free to bring an instrument or your own data

Formulation and Delivery

Panel Discussion: Moving Beyond Oral Delivery

 

•    Nanoparticles
•    Inhalation
•    Transdermal
•    Developments with Oral Delivery

Confirmed Panellist: Shadi Farhangrazi, Chief Executive Officer
Confirmed Panellist: Joël Richard, Chief Development Officer, Enterome SA

Roundtable: Successes And Pitfalls With AI In Drug Discovery And Development


•    Landscape
•    Future Uses
•    Enhancing Drug Development

Roundtable: Challenges Within RNA Delivery And Lessons Learned From Failure


•    How we can learn from previous case studies
•    What are the current priorities for the RNA therapeutics industry
•    How can the RNA field work together to overcome this

Key Event Highlights

An unmissable journey awaits you: from award winning speakers and insightful workshops, to an exclusive gala dinner. Discover the moments that will transform your Discovery & Development experience. 

Drug Discovery
Biologics & Small Molecule Drug Discovery Modalities
Roundtable: PROTACs – Drugging The ‘Undruggable’

•    Enhancing PROTAC design, potency & safety
•    Delivery challenges
Roundtable: The Future Of Antibody-Drug Conjugates (ADCs)
•    Enhancing ADC design, potency & safety
•    Delivery challenges

Advancements in Screening

Panel Discussion: Novel Platforms & Techniques To Improve Hit Identification
•    Optimising Hit discovery
•    Minimising false positives
•    Integration of techniques

Innovation and Partnership
Panel Discussion: Fostering Partnerships & Collaboration In 2025 – as part of our newly introduced Early-Stage R&D Innovation Programme

•    Emerging technologies & techniques
•    Cross-sector partnership
•    Open innovation
Moderated by Alexander Natz, Secretary General, EUCOPE

M&A and Investments in Drug Discovery & Development
Panel Discussion: The Investment Landscape In 2025 – Time To Rethink?

•    Importance of aligning scientific innovation with commercial potential
•    Emerging strategies

Panellists include Christoph Rösli, Director of Research Bern, CSL Behring & Member of the Selection Board, BaseLaunch; David Jenkinson, Head of Childhood Cancer Translational Challenge, LifeArc; David Dexter, Director of Research, Parkinsons UK & more to be confirmed!

AI & Drug Discovery Advances
Panel Discussion: AI-Powered Technological Advancements For Novel Target Discovery

•    Novel platforms & techniques to identify new targets
•    Utilising AI/ML
•    Challenges & future opportunities
Panellists:
Giovanni Spagnolli, Chief Technology Officer, Sibylla Biotech
Ian Roberts, Director of Therapeutic Technology, Healx

Neuro Degenerative Diseases & Immunology in Focus
Panel Discussion:
Fostering Collaboration To Accelerate Neurodegenerative Disease Research

•    Pharma, biotech & academic partnerships
•    The need for innovation, data & technology in CNS research
•    Challenges to be solved through collaboration 
Moderated by Emma Mead, Chief Scientific Officer, Alzheimer’s Research UK Oxford Drug Discovery Institute, University of Oxford. Panellists include Knut Biber, Research Fellow & Head of Glial Biology Team, AbbVie; Sarah Jolly, Principal Scientist, LifeArc; Michael Johnson, Professor of Neurology & Genomic Medicine, Imperial College London

Panel Discussion:
Fostering Collaboration To Accelerate Neurodegenerative Disease Research
•    Beyond blood-based biomarkers?
•    Are we any closer to a solution?
•    Application of AI/ML
Moderated by Manuela Cerina, Scientific Director – Neurodegeneration, LifeArc & Giovanna Lalli, Director of Strategy & Operations, LifeArc

Automation in Focus
Panel Discussion:
Automation & Robotics In Drug Discovery & Development – Where Are We Now? 

•    Impact of automation 
•    AI/ML  
•    Robotics in lab processes
Moderated by Rekha Lakshmanan, Global Head of Data Office, AstraZeneca

Day 2 Breakfast Workshop: SiLA & AnIML Splash

•    Splash! Is a unique event for every digital lab enthusiast. It combines an educational part with a hands-on session to try out standards in action. Pick up the details on the popular SiLA and AnIML standards, understand how they work and where you can put them to use. Our hands-on session lets you experience the standards in action firsthand. We’re bringing real and cloud-based instruments and lots of example data sets
•    Feel free to bring an instrument or your own data

•    Importance of aligning scientific innovation with commercial potential
•    Emerging strategies

Panellists include Christoph Rösli, Director of Research Bern, CSL Behring & Member of the Selection Board, BaseLaunch; David Jenkinson, Head of Childhood Cancer Translational Challenge, LifeArc; David Dexter, Director of Research, Parkinsons UK & more to be confirmed!

AI & Drug Discovery Advances
Panel Discussion: AI-Powered Technological Advancements For Novel Target Discovery

•    Novel platforms & techniques to identify new targets
•    Utilising AI/ML
•    Challenges & future opportunities
Panellists:
Giovanni Spagnolli, Chief Technology Officer, Sibylla Biotech
Ian Roberts, Director of Therapeutic Technology, Healx

Who is Speaking at Discovery & Development Europe 2025?

Andreas Gryczke
Director, Process Engineering,
AbbVie
Davide Gianni
Senior Director,
AstraZeneca
Emma Mead
Chief Scientific Officer, Oxford Drug Discovery Institute,
University of Oxford
Heinrich Haas
Chief Technology Officer,
Neovacs
Morten Grunnet
Vice President, Head of Neuroscience,
Lundbeck
Philippe Marc
Executive Director, Global Head of Integrated Data Sciences,
Novartis
Rekha Lakshmanan
Global Head of Data Office,
AstraZeneca
Shadi Farhangrazi
Chief Executive Officer,
S.M. Discovery Group
Sorina Morar-Mitrica
Director Science & Technology,
Novartis
Stephen Pham
Senior Vice President,
Avalyn Pharma Inc.
Ulrich Betz
Vice President Innovation,
Merck
Vineeta Tripathi
Chief Executive Officer,
Vitarka Therapeutics
Abhishek Choudhary
Principal Data Engineer,
Bayer
Alain Martelli
Director External Science and Innovation, France,
Pfizer
Alexander Natz
Secretary General,
EUCOPE
Amal Ali Elkordy
Professor of Pharmaceutics,
University of sunderland
Andreas Bernkop Schnurch
Professor,
University of Innsbruck
Andrew Woodhead
Head of Chemistry,
Astex Pharmaceuticals
Andy Pike
Senior DMPK Discovery and Development Lead, Director,
AstraZeneca
Anna-Pia Papageorgiou
Policy Officer, Health Innovations & Ecosystems, DG Research & Innovation,
European Commission
Antonia Stepan
Section Head, Medicinal Chemistry,
China Innovation Center of Roche
Arne Skerra
Professor,
Technische Universität München
Bobby Soni
CIO,
BioInnovation Institute
Burkhard Schäfer
Managing Director & Director at SiLA,
splashlake.com
Christine Maurer
Scientific Associate Director Biotransformation,
Merck & Cie KmG
Christoph Rösli
Director Research,
CSL Behring & BaseLaunch
Chuang Kee Ong
Director Data Product,
GSK
Covadonga Paneda
Chief Operating Officer,
Altamira Therapeutics
Dan Hardy
Chief Executive Officer,
Microsol Ltd
Daniel Tondera
Head of Biology,
Pantherna Therapeutics
David Jenkinson
Head of Childhood Cancer Translational Challenge,
LifeArc
David Dexter
Research Director,
Parkinson's UK
Duane Schulthess
CEO,
Vital Transformation
Enrico Zambelli
Sustainable Formulations Unit Manager,
chiesi farmaceutici
Eric Lorent
Senior Scientist,
Sanofi
Estelle Beguin
Director Technology Research,
Ethris
Farshad Ramazani
Senior Expert Science & Technology,
Novartis Pharma
Florian Ries
Senior Scientist II,
AbbVie
Giovanna Lalli
Director, Strategy & Operations,
LifeArc
Giovanni Spagnolli
Chief Technology Officer,
Sibylla Biotech
Helen Bright
Chief Scientific Officer,
Centauri Therapeutics
Holger Kubas
Director Research Pharmaceutics,
Merck US
Ian Roberts
Director of Therapeutic Technology,
Healx
Jack Doolan
Investigator,
GSK
James Dale
Director of Drug Discovery,
PharmEnable Therapeutics
Jean Ge
Patent Attorney,
Wolf Greenfield
Jens Twellmeyer
Associate Director Science & Technology,
Novartis AG
Jessica Yu
Senior Scientist,
AstraZeneca
Joel Richard
Chief Development Officer,
Enterome
Jonathan Hopper
Vice President, Platforms & Founder,
OMass Therapeutics
Jörg Berghausen
Associate Director,
Novartis
Juha Monkare
Sr. Scientist,
J&J
Kamalinder Kaur Singh
Professor of Pharmaceutical Technology and drug delivery,
https://www.uclan.ac.uk/?msclkid=75cded44b4e311ecbaf6958f72df03d3
Karsten Maeder
Professor,
Martin Luther University Halle-Wittenberg
Katarzyna Malik
R&D Director,
Polpharma
Knut Biber
Research Fellow & Head of Glial Biology Team,
AbbVie
Lars van der Veen
Chief Scientific Officer,
ionctura
Lubor Gaal
Chief Financial Officer & Chief Business Officer,
Circio
Maeve Caldwell
Professor in Neuroscience, Physiology,
Trinity College Dublin
Manuela Cerina
Scientific Director - Neurodegeneration,
LifeArc
Maria Levitin
Director of RNA Oligonucleotide Delivery, Genetic Medicine,
Grünenthal GmbH
Marius Lutz
Scientist, High-Throughput Experimentation, Chemical Reaction Screening,
Hoffmann La Roche Ltd
Meike Harms
Lead Scientist,
Merck KGaA
Meiling Li
Technical project leader,
F.Hoffmann-La Roche
Michael Johnson
Professor of Neurology and Genomic Medicine,
Imperial College London
Moein Moghimi
Professor of Nanomedicine and Pharmaceutics, School of Pharmacy,
Newcastle University
Natasha Drapeau
Managing Director & Co-Founding Senior Partner, Cohesion Bureau,
Cohesion Bureau
Paulina Kolasinska-Zwierz
Principal Scientist,
Alchemab
Peng Leong
CBO and Head of Brain Aging,
Bioage labs
Phil Noble
Head of Single B Cell Antibody Discovery,
UCB Pharma
Philip Hewitt
Global Head of Early Investigative Toxicology,
Merck
Poppy Winlow
Senior Research Scientist,
AstraZeneca
Rainer Wilcken
Director, Computational Chemistry,
Flare Therapeutics Inc
Rajaa Sukhun
Senior Director of Research DMPK,
Cytokinetics
Ramesh Kashi
Consultant,
Self Employed
Raul Rodriguez
Vice President,
Woxsen University
Rene van Nostrum
Professor,
Utrecht University
Rick Ewing
VP, Head of Chemistry,
Rapafusyn Pharmaceuticals
Robin Loving
Chief Scientific Officer,
Salipro Biotech AB
Roderick Beijersbergen
Head of NKI Genomics Core Facility & Professor of Functional Genomics,
The Netherlands Cancer Institute
Sabine Kuratli
CMC Lead,
CEPI
Saif Shubber
Associate Director,
Bicycle Therapeutics
Sandor Batkai
Co-founder, Head of Medical Research and Intelligence,
Cardior Pharmaceuticals GmbH
Sarah Jolly
Principal Scientist,
LifeArc
Shayoni Dutta
Data Science Manager,
GLAXOSMITHKLINE
Simone Vecchi
Associate Director - Drug Product Development Scientific Integrator,
Johnson & Johnson Innovative Medicine
Simone Tortoioli
Senior CMC Director,
Monte Rosa Therapeutics Inc
Sophie Janbon
Director,
AstraZeneca
Stefan Mueller
Global Head Nonclinical Safety,
LES LABORATOIRES SERVIER
Stefan Schiesser
Director of Medicinal Chemistry,
AstraZeneca
Stephanie Harlfinger
Senior Director, Global Head NCE DMPK,
Merck & Cie KmG
Supriyadi Hafiz
Senior Scientist,
Merck
Suruchi Vishwasrao
Senior Scientist,
Merck Life Science Pvt. Ltd.
Tanvir Tabish
Director, Early Formulation Development,
Boehringer Ingelheim RCV GmbH & Co KG
Thanneer Malai Perumal
Senior Principal Scientist,
Hoffmann La Roche Ltd
Tjasa Vrlinic
PI,
Medincell
Tom Kissling
pRED Automation Partner & Director at SiLA,
F. Hoffmann-La Roche AG
Toria Legh-Land
Computational Pharmaceutics Lead,
Microsol
Trond Ulven
Professor,
Copenhagen University
Varun Kushwah
Principal Scientist,
RCPE
Vik Reebye
Head of Academic Partnership,
MiNA Therapeutics Ltd
Virginia Ballotta
New Ventures Manager,
BaseLaunch
Yi Sun
Associate Professor,
Technical University of Denmark
Zeeshan Ahmad
Professor,
De Monfort University

Sponsors

Interested in Sponsoring Discovery & Development?

Become a driving force in accelerating the volume of safe, effective first-in-class drugs to reach patients. Discovery & Development offers a unique platform to enhance your brand visibility and connect with thousands of biopharma decision-makers. Our branded event opportunities, immersive experiences, and content services enable you to engage, educate, and collaborate with the innovators shaping the future of R&D today

Interested in Sponsoring NextGen Biomed?

Become a driving force in accelerating the next generation of biologics and immunotherapy medicines to patients. NextGen Biomed offers a unique platform to enhance your brand visibility and connect with thousands of pharma, biotech, and R&D experts. Our branded event opportunities, immersive experiences, and content services enable you to engage, educate, and collaborate with the community shaping the future of biomedicine today.


f9d83b55-ff87-4538-a4e2-f67b63da4765-2-5668375logo-Axion-Logo_Tagline_2022

 

Good number of 1-1 meetings with relevant people. Very happy with the networking process and the Oxford Global team are very nice and service minded.


Regional Sales Director
AxionBio

5a563b71-261f-4b78-a13b-5b4890a6b41d-2-5668375logo-Copy-of-Arctoris-blue-logo-1-Transparent

 

Absolutely outstanding conference attracting large pharma and aspiring biotechs. Oxford Global are excellent, the food is outstanding and the preset meetings are informal and impactful

Vice President of Business Development
Arctoris

Novalix Logo

 

The organisation was perfect. Good mix between excellent scientific presentations and network opportunities.


Pharmacology Associate Director
Novalix

novartis-logo

 

This was my first time at the conference and it was a great experience. Very well organized conference and I learned a lot and made valuable connection - Thank you Oxford Global.


Senior Principal Scientist

Novartis

GenScript

The 1-2-1s are the best thing about Oxford Global events, well organised and good number of relevant contacts. Good high level contacts from big companies.

 

Advanced Therapies Specialist Team Leader,
Genscript

Biosystems Acro

Biologics 2024 has been one of the best events I have attended so far in my career.

 

Territorial Sales Manager UK,
ACROBiosystems Co., Ltd.

Bioassay

 

Impressed by the effort to bring people together.

 

Business Development Director,

Bioassay

IpA

 

Nice set-up, with good support for exhibitors

 

Director of Client Relations,

ImmunoPrecise

New Opportunities

The Start-up Zone

Are you developing a cutting-edge therapy, platform or technology? Our Start-Up Zone is designed to support emerging companies looking to increase their visibility, find potential partners or early adopters, and meet their investment goals – connecting them with our community of pharma, investors, and mid-to-large size biotechs. 

Located in the Exhibition Hall, the Start-Up Zone allows therapeutic pioneers to showcase their approach, conduct invaluable 1:1 meetings and deliver a quick-fire pitch.

There are two options, based on the size of your organisation with prices starting from €1800. 

For further information and to get started submit the application form below.

Criteria:

The Start-Up Zone is designed for therapeutic start-ups, academic spin-outs, and early-stage technology/service providers.

 

To be eligible for inclusion, you must meet the following criteria:

 

•    0 – 5 years operating
•    0 – 30 employees
•    Pre-Series A funding


What you will receive:

  • 1 full conference pass
  • 10-minute pitch on the Start-Up Stage
  • 1x1m space in Start-Up Zone for own partnering meetings; cocktail table provided, start-up to bring 1x pull-up banner
  • Logo featured on website & event platform as a participating start-up
  • Ability to arrange 1:1 meetings via the congress app

2025 Young Scientist Awards (YSA) for Best Poster Presentation

The NextGen Biomed Young Scientist Awards include the best poster presentation award and are intended to honour an outstanding individual performance for a scientific work by a PhD student, PostDoc or early career scientist.

Please submit your poster presentation by no later than 13th January 2025 in the below category:

  • Protein/Antibody Engineering
  • Bioanalysis & Characterisation
  • Next Generation Biotherapeutics
  • Peptides Chemistry & Therapeutics
  • Oligonucleotides Chemistry & Therapeutics
  • Sustainable Chemistry & Manufacturing
  • Student (PhD), PostDoc or early career scientist under 35 years of age. Proof must be provided via an active student ID card or a copy of status
  • Applicants must be the first AND presenting author of the submitted paper and register for the meeting by 13th January 2025
  • ONLY ONE YSA submission per person will be accepted. If authors submit multiple abstracts for consideration for the YSA, only one abstract will be taken into consideration for the YSA

Applicants must follow the procedure as follows: 

  • Register and submit an abstract by 13th January 2025 using the registration link to the left on this page 
  • Once registered you will be provided with the online abstract submission form 
  • Prepare the poster or platform and present it (The poster presenter should be at the poster during all breaks.) 
  • The 3 winners with the highest scores will be announced at the Networking Drinks on the second day of the event 
  • The winners’ 10-minute oral presentations will take place during the networking drinks on day 2 

The platform or poster presentation will be evaluated by senior scientists (consisting of our speaking and steering group committee for the NextGen Biomed series) on the basis of originality of the approach and quality of the work (e.g. appropriate methodology, interpretation of results, conclusiveness). All participants will receive the scoring and comments after the annual meeting via email.

The 3 winners receiving the highest scores will be announced at the Networking Drinks on the Day 2 and will be given a trophy as well as £1,000 contribution towards travel costs. Oxford Global will also provide winners with PLUS Pass – 12 months access to our content platform providing access to on-demand presentations, exclusive reports and highlights. 

Plan Your Visit

Congress Center Basel
MCH Swiss Exhibition (Basel) Ltd. Messeplatz 21, CH-4058 Basel

By Rail

Basel is an international rail hub with direct ICE, IC and EC connections to Germany, Austria, Italy, France and the Benelux countries. Messe Basel can be reached in five to ten minutes from the three railway stations in Basel: SBB (Switzerland), SNCF (France) (Frankreich) and DB (Badischer Bahnhof, Germany)

By Tram

From the SBB/SNCF railway station, it’s a ten-minute journey on the No. 1 or 2 Tram to the “Messeplatz/Exhibition Square” stop where Messe Basel and the Congress Center are located. From Badischer Bahnhof railway station, “Messeplatz/Exhibition Square” is the second stop on the No. 2 or 6 tram.

By Air

EuroAirport Basel-Mulhouse-Freiburg is 15 minutes by car from Messe Basel. Basel municipal transport’s No. 50 bus additionally provides a straightforward connection from the airport to the SBB/SNCF railway station. From there, tram No. 1 or 2 will take you directly to Messeplatz/Exhibition Square. From Zurich Airport a direct rail connection will bring you to the SBB/SNCF railway station in Basel in less than an hour. For further information including a map and full directions, please visit: https://www.messe-basel.com/en/about-us/getting-to-messe-basel/

By Car

Basel is located at the point where the Swiss, German and French motorway networks all meet. The exhibition and congress site has its own direct link to the A2 motorway. The “Messe” exit will take you straight to the Messe Basel car park with its 1,200 parking spaces.

Oxford Global has secured a number of bedrooms at the Basel Marriott Hotel at a reduced conference rate: 

 

  • Sunday 22nd June 2025 – £265 (Including Breakfast & City Tax)
  • Monday 23rd June 2025 – £265 (Including Breakfast & City Tax)
    *Please note: £30 supplement is applicable for double occupancy

 

Should you wish to book a room, please email help@oxfordglobal.com

 

The final cut-off date to book bedrooms is Monday 2nd June 2025 – any bookings after this date are subject to availability and rates. Please note that any cancellations within 14 days prior to arrival are subject to full cancellation charges.

We are closely monitoring the official guidance from health authorities, local governments, and the World Health Organization in order to support the health and well-being of our global community. The health and safety of our staff, customers and clients remains our number one priority.

As we continue to move forward with hosting our events in-person in 2025, we’ve added a series of Health & Safety guidelines and precautions in order to prepare for event safety. We carry out risk assessments for all our events to evaluate fundamental considerations and how to cover multiple risk scenarios.

Oxford Global has learned that third-party companies (recently EHotel Services, Business Travel Management/btravelmanagement and Exhibitors Hotel Reservations Services) are targeting conference attendees with a fraudulent hotel booking scheme.

Please note that none of these third-party companies are associated with Oxford Global in any way, nor have Oxford Global authorised them to use their names or trademarks on information they send out to attendees.

If you are contacted by a third-party company by phone or email using Oxford Global’s name or the name of Discovery & Development Europe 2025 and offering accommodation services, we urge exhibitors and attendees to proceed with extreme caution before signing anything sent by these companies or entering into any conversation or replying to any emails sent from these third-party companies.

Interested in Discovery & Development 2025?